Literature DB >> 23903573

Immunotherapy exposes cancer stem cell resistance and a new synthetic lethality.

Laszlo Radvanyi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23903573      PMCID： PMC3740219          DOI： 10.1038/mt.2013.160

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  16 in total

1.  Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes.

Authors:  Xinsheng Liao; Yongqing Li; Chiara Bonini; Smita Nair; Eli Gilboa; Philip D Greenberg; Cassian Yee
Journal:  Mol Ther       Date:  2004-05       Impact factor: 11.454

Review 2.  EMT: when epithelial cells decide to become mesenchymal-like cells.

Authors:  Raghu Kalluri
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

Review 3.  Resistance to BRAF-targeted therapy in melanoma.

Authors:  Ryan J Sullivan; Keith T Flaherty
Journal:  Eur J Cancer       Date:  2013-01-02       Impact factor: 9.162

Review 4.  INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.

Authors:  Alberto A Chiappori; Hatem Soliman; William E Janssen; Scott J Antonia; Dmitry I Gabrilovich
Journal:  Expert Opin Biol Ther       Date:  2010-06       Impact factor: 4.388

5.  Calreticulin exposure dictates the immunogenicity of cancer cell death.

Authors:  Michel Obeid; Antoine Tesniere; François Ghiringhelli; Gian Maria Fimia; Lionel Apetoh; Jean-Luc Perfettini; Maria Castedo; Grégoire Mignot; Theoharis Panaretakis; Noelia Casares; Didier Métivier; Nathanael Larochette; Peter van Endert; Fabiola Ciccosanti; Mauro Piacentini; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Med       Date:  2006-12-24       Impact factor: 53.440

Review 6.  Cancer immunotherapy with mRNA-transfected dendritic cells.

Authors:  Eli Gilboa; Johannes Vieweg
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

7.  Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.

Authors:  Florian Reim; Yvonne Dombrowski; Cathrin Ritter; Mathias Buttmann; Sebastian Häusler; Monika Ossadnik; Mathias Krockenberger; Dagmar Beier; Christoph P Beier; Johannes Dietl; Jürgen C Becker; Arnd Hönig; Jörg Wischhusen
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

8.  Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.

Authors:  Alexander Roesch; Adina Vultur; Ivan Bogeski; Huan Wang; Katharina M Zimmermann; David Speicher; Christina Körbel; Matthias W Laschke; Phyllis A Gimotty; Stephan E Philipp; Elmar Krause; Sylvie Pätzold; Jessie Villanueva; Clemens Krepler; Mizuho Fukunaga-Kalabis; Markus Hoth; Boris C Bastian; Thomas Vogt; Meenhard Herlyn
Journal:  Cancer Cell       Date:  2013-06-10       Impact factor: 31.743

9.  Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.

Authors:  Jose Pulido; Timothy Kottke; Jill Thompson; Feorillo Galivo; Phonphimon Wongthida; Rosa Maria Diaz; Diana Rommelfanger; Elizabeth Ilett; Larry Pease; Hardev Pandha; Kevin Harrington; Peter Selby; Alan Melcher; Richard Vile
Journal:  Nat Biotechnol       Date:  2012-03-18       Impact factor: 54.908

10.  Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.

Authors:  Nicolas Boisgerault; Timothy Kottke; Jose Pulido; Jill Thompson; Rosa Maria Diaz; Diana Rommelfanger-Konkol; Addie Embry; Dyana Saenz; Eric Poeschla; Hardev Pandha; Kevin Harrington; Alan Melcher; Peter Selby; Richard Vile
Journal:  Mol Ther       Date:  2013-06-11       Impact factor: 11.454
View more
  4 in total

1.  The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression.

Authors:  Limo Chen; John V Heymach; F Xiao-Feng Qin; Don L Gibbons
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

Review 2.  Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells.

Authors:  Katherine Woods; Anupama Pasam; Aparna Jayachandran; Miles C Andrews; Jonathan Cebon
Journal:  Front Oncol       Date:  2014-12-17       Impact factor: 6.244

3.  Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells.

Authors:  Nabanita Mukherjee; Yan Lu; Adam Almeida; Karoline Lambert; Chung-Wai Shiau; Jung-Chen Su; Yuchun Luo; Mayumi Fujita; William A Robinson; Steven E Robinson; David A Norris; Yiqun G Shellman
Journal:  Oncotarget       Date:  2017-07-18

4.  Integrated Analysis of Energy Metabolism Signature-Identified Distinct Subtypes of Bladder Urothelial Carcinoma.

Authors:  Fan Zhang; Jiayu Liang; Dechao Feng; Shengzhuo Liu; Jiapei Wu; Yongquan Tang; Zhihong Liu; Yiping Lu; Xianding Wang; Xin Wei
Journal:  Front Cell Dev Biol       Date:  2022-02-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.